Pharmacokinetics of trimetrexate and dapsone in aids patients with Pneumocystis carinii pneumonia

Journal of Clinical Pharmacology

Volumn 39, Issue 3, 1999, Pages 268-274

  Koda, Robert T ^a   Dubé, Michael P ^b   Li, Wen Yen ^b   Chatterjee, Dhruba J ^b   Stansell, John D ^b   Sattler, Fred R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; DAPSONE; DAPSONE DERIVATIVE; FOLINIC ACID; PREDNISONE; TRIMETREXATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLITE; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DAPSONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; PNEUMONIA, PNEUMOCYSTIS; TRIMETREXATE;

EID: 0032978504     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chan ISF, Neaton JD, Saravolatz LD, Crane LR, Osterberger J: Frequencies of opportunistic diseases prior to death among HIV-infected persons. AIDS 1995;9:1145-1151.
2. Shapiro J, Simon P: Late HIV diagnosis and failure to receive chemoprophylaxis against Pneumocystis carinii pneumonia. Program Abstr Intersci Conf Antimicrob Agents Chemotherp 1996;203.
3. Hughes WT, Leoung G, Kramer F, Bonzzette SA, Safin S, Frame P, et al: Comparison of atovaquone (566C80) with trimethoprimsulfamethoxazole for the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome (AIDS). N Engl J Med 1993;328:1521-1527.
4. Montgomery AB, Feigal DW, Sattler FR, Mason FA, Catanzaro A, Edison R, et al: Pentamidine aerosol versus trimethoprimsulfamethoxazole for Pneumocystis carinii in acquired immunodeficiency syndrome. Am J Respir Crit Care Med 1995;151:1068-1074.
5. Sattler FR, Cowan R, Nielsen DM, Ruskin J: Trimethoprimsulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, non-crossover study. Ann Intern Med 1988;109:280-287.
6. Sattler FR, Frame P, Davis R, Nichols L, Shelton B, Akil B, et al: Comparison of trimetrexate with leucovorin versus trimethoprimsulfamethoxazole for moderate-to-severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a randomized, double-blind multicenter investigation of the AIDS Clinical Trials Group (ACTG) protocol 029/031. J Infect Dis 1994;170:165-172.
7. O'Brien JG, Dong BJ, Coleman RL, Gee L, Galanco KB: A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who are receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997;24:954-959.
8. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H: Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987;165:926-931.
9. Sattler FR, Allegra CJ, Verdegem TD, Akil B, Tuazon CU, Hughlett C, et al: Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. J Infec Dis 1990;161(1):91-96.
10. Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, et al: Trimetrexate for treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. N Engl J Med 1987;317:978-985.
11. Brun-Plascaud M, Chau F, Carry L, Farinotti R, Derouin F, Girard P-M: Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. J Acquir Immun Defic Syndr Human Retrovirol 1996;13:210-217.
12. Hughes WT, Smith BL: Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1988;32:623-625.
13. Hughes WT: Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1988;32:323-325.
14. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, et al: Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprimsulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-782.
15. Stansell JD, Dube MP, Sharpe E, Sattler FR: Randomized phase I trial of trimetrexate glucuronate, leucovorin plus dapsone versus trimethoprim/sulfamethoxazole for treatment of moderate to severe Pneumocystis carinii pneumonia. Program Abstr 35th Intersci Conf Antimicrob Agents Chemother 1995;LM95.
16. Ackerly CC, Hartshom J, Tong WP, McCormack JJ: A rapid and sensitive method for determination of trimetrexate from biological fluids. J Liquid Chromatogr 1985;8(1):125-134.
17. Hudes GR, LaCreta F, Walczak J, Tinsley P, Litwin S, Comis RL, et al: Pharmacokinetic study of trimetrexate in combination with cisplatin. Cancer Res 1991;51:3080-3087.
18. Horai Y, Ishizaki T: Rapid and sensitive liquid chromatographic method for the determination of dapsone and monoacetyldapsone in plasma and urine. J Chromatogr 1985;345:447-452.
19. Lemnge MM, Ronn A, Flachs H, Bygbjerg Ib C: Simultaneous determination of dapsone, monoacetyldapsone and pyrimethamine in whole blood and plasma by high-performance liquid chromatography. J Chromatogr 1993;613:340-346.
20. Carr K, Oates, JA, Nies AS, Woosley RL: Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol 1978;6:421-427.
21. Stewart JA, McCormack JJ, Tong WW, Low JB, Roberts JD, Blow A, et al: Phase I clinical and pharmacokinetic study of trimetrexate using a daily × 5 schedule. Cancer Res 1988;48:5029-5035.
22. Lin JT, Cashmore AR, Baker MA, Dreyer RN, Ernstoff M, Marsh JC, et al: Phase I studies with trimetrexate: clinical pharmacology, analytical methodology and pharmacokinetics. Cancer Res 1987;47:609-616.
23. Ho DHW, Covington WP, Legha SS, Newman RA, Krakoff IR: Clinical pharmacology of trimetrexate. Clin Pharmacol Ther 1987;42(3):351-356.
24. Hudes GR, LaCreta FP, DeLap RJ, Grillo-Lopez AJ, Catalano R, Comis RL: Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. Cancer Chem Pharm 1989;24:117-122.
25. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM: Clinical pharmacokinetics of dapsone. Clin Pharmacokinetics 1986;11:299-315.
26. Lammintausta K, Kangas L, Lammintausta R: The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva. Internat J Clin Pharmacol Biopharm 1979;7(4):159-163.
27. Pieters FAJM, Zuidema J: The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol 1086;22:491-494.